Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 02-0478229 (State or other jurisdiction of (I.R.S. Employ ...

EXHIBIT 99.1 Investor Contact: Nathan Harrill Exact Sciences Corp. investorrelations@exactsciences.com 608-535-8659 Media Contact: Morry Smulevitz Exact Sciences Corp. msmulevitz@exactsciences.com 608-345-8010 For Immediate Release Exact Sciences Announces First-Quarter 2024 Results First quarter highlights • Delivered total first quarter revenue of $638 million, an increase of 6% on a reported and core revenue basis, including Screening revenue of $475 million and Precision Oncology revenue of $163 million ...

In the latest market close, Exact Sciences (EXAS) reached $63.24, with a -0.46% movement compared to the previous day. This change lagged the S&P 500's daily gain of 0.02%. Meanwhile, the Dow experienced a drop of 0.11%, and the technology-dominated Nasdaq saw an increase of 0.1%.Shares of the molecular diagnostics company witnessed a loss of 2.62% over the previous month, beating the performance of the Medical sector with its loss of 4.52% and the S&P 500's loss of 3.01%.Analysts and investors alike will b ...

Exact Sciences (EXAS) is set to report its first-quarter 2024 results on May 8, after the closing bell.Earnings Surprise HistoryExact Sciences has an impeccable earnings surprise history so far. The company beat earnings estimates in each of the last four trailing quarters, delivering an average earnings surprise of 51.48%.The Zacks Consensus Estimate for first-quarter 2024 loss per share is pegged at 50 cents. The consensus estimates for first-quarter revenues of $624.9 million.Before we get into what to e ...

In the latest market close, Exact Sciences (EXAS) reached $63.22, with a -1% movement compared to the previous day. This change lagged the S&P 500's daily loss of 0.58%. Elsewhere, the Dow saw a downswing of 0.12%, while the tech-heavy Nasdaq depreciated by 1.15%.Prior to today's trading, shares of the molecular diagnostics company had gained 3.17% over the past month. This has outpaced the Medical sector's loss of 6.07% and the S&P 500's loss of 1.09% in that time.The investment community will be closely m ...

Full disclosure, I’m not a tremendous fan of Cathie Wood. Generally, I think she makes some terrible picks. For example, what many would consider the best Cathie Wood stocks to buy in April, and her two largest holdings were Coinbase (NASDAQ:COIN) and Tesla (NASDAQ:TSLA). Both companies’ valuations are in the stratosphere. And Coinbase is facing tremendous competition from Bitcoin (BTC-USD) ETFs, along with a potentially ruinous lawsuit by the SEC. Meanwhile Tesla is struggling amid a huge amount of competi ...

This company is innovating where it matters most, which could prove highly lucrative down the road.Cancer diagnostic specialist Exact Sciences (EXAS -0.04%) has lagged the market over the past three years. The pandemic and the economic troubles that followed disrupted the company's operations, and the healthcare leader remains unprofitable. However, one famous name on Wall Street continues to have faith in Exact Sciences.That person is Cathie Wood, CEO of Ark Invest, an investment management firm that still ...

Exact Sciences Corporation (EXAS) recently reported a promising outcome for the non-endoscopic Oncoguard Esophagus test, developed in collaboration with the Mayo Clinic Comprehensive Cancer Center. The test, currently in development for the detection of esophageal adenocarcinoma (EAC) and its precursors, including Barrett’s esophagus (BE), has demonstrated high sensitivity and specificity.The findings from the test’s algorithm training and testing were recently published in the Clinical Gastroenterology and ...

A month has gone by since the last earnings report for Exact Sciences (EXAS) . Shares have added about 4.2% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Exact Sciences due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Exact Sciences Q4 Loss Narrows, Revenues Rise ...

Exact Sciences Corporation (EXAS) recently announced the online publication of the BLUE-C study results in The New England Journal of Medicine (NEJM). The 20,000-participant, multi-center and prospective study was designed to determine the performance characteristics of the company’s next-generation Cologuard Plus multitarget stool DNA test.The publication of the "Next-Generation Multitarget Stool DNA Test for Colorectal Cancer (CRC) Screening" peer-reviewed study in NEJM reflects a decade of Exact Sciences ...